Jared Kaltwasser

Only about 10 cases of hypoparathyroidism related to systemic lupus erythematosus (SLE) have been reported, according to researchers who recently described such a case.

A new report finds inflammation scores can predict outcomes among patients receiving immunotherapy for intrahepatic cholangiocarcinoma (ICC).

However, the researchers said their findings should not be interpreted as completely refuting the possibility that hydroxychloroquine might be a useful tool in preventing or slowing the development of systemic lupus erythematosus (SLE).

Risk for individual hepatobiliary cancers varies from comorbidity to comorbidity, researchers found.

The study found that combined therapeutic strategies may help lower the risk.

Among the challenges are a lack of reliable biomarkers and resistance in some patients who have squamous cell carcinoma (SCC).

The question of whether bone erosion is a feature of Jaccoud arthropathy has remained controversial among persons who have systemic lupus erythematosus (SLE).

The survey of European hepatologists demonstrates the lack of clarity in guidelines.

Molecular differences may help explain geographic gaps in outcomes.

The research shows a disease-specific quality-of-life (QOL) tool is more sensitive than a generic version.

A new report finds despite reforms to the country’s health care system, many patients in China with lung cancer experience stress, and sometimes health consequences, on account of the disease’s financial burden.

Leptin merely correlated with body mass index, the study found.

The study could provide an important baseline of what the disease looked like before the advent of disease-modifying therapies.

Patients in the highest risk category had a 65% chance of recurrence of their perihilar cholangiocarcinoma (PHCC) within 1 year, this new study has found.

Only about 11% of patients received care meeting a composite quality metric, a study found.

The patient was successfully treated with rituximab and intravenous immunoglobulin.

However, patient-reported scores were not significantly better in the tocilizumab group.

A new study looks at the balancing act physicians and families must carry out when managing expectations at a time of great scientific advancement in spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD).

At 12 weeks, nearly 8 in 10 patients had significant improvement.

The case involved a 69-year-old man who presented with lupus nephritis.

A new review article explains the role of biologics in treatment systemic lupus erythematosus (SLE) and lupus nephritis.

New data show litifilimab outperformed placebo in patients with active arthritis and skin manifestations due to systemic lupus erythematosus (SLE).

About 4 in 10 patients do not receive curative therapy despite early detection, a new study shows.

A study carried out at 4 health care systems found rates of stage I lung cancer increased, and rates of stage IV cancer decreased, once screening was initiated.

Chimeric antigen receptor (CAR) T-cell therapies may help patients with otherwise refractory cases of multiple myeloma, but patients must overcome significant hurdles to access the therapy.

This study suggests that the diaphragm may fare differently from other muscles in spinal muscular atrophy (SMA).

The authors found the association by comparing echocardiographic and biochemical changes after 5 years in patients with systemic lupus erythematosus (SLE).

The findings suggest that sequential mutant IDH inhibitor therapy might be one way to fight resistance in metastatic intrahepatic cholangiocarcinoma (IHCC).

A new therapeutic paradigm has heightened the need for meaningful measures of assessing patients.

A new study finds anxiety and depression are more common in people with systemic lupus erythematosus (SLE) if they also have nephritis.